Loading clinical trials...
Loading clinical trials...
Efficacy and Safety of X-396 (Ensartinib) in ALK-Positive NSCLC Patients With Brain Metastases: A Phase Ⅱ, Open-Label, Single Arm, Multicenter Study
Conditions
Interventions
X-396(Ensartinib)
Locations
1
China
Fudan University Shanghai Cancer Center
Shanghai, China
Start Date
March 21, 2019
Primary Completion Date
December 1, 2020
Completion Date
June 1, 2021
Last Updated
June 4, 2020
NCT05692635
NCT07464470
NCT05987644
NCT05419076
NCT05139277
NCT04923542
Lead Sponsor
Betta Pharmaceuticals Co., Ltd.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions